Geneos Wealth Management Inc. Purchases 649 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Geneos Wealth Management Inc. raised its stake in IQVIA Holdings Inc. (NYSE:IQV) by 5.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 12,138 shares of the medical research company’s stock after acquiring an additional 649 shares during the period. Geneos Wealth Management Inc.’s holdings in IQVIA were worth $3,070,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the stock. Los Angeles Capital Management LLC lifted its stake in IQVIA by 17.5% in the fourth quarter. Los Angeles Capital Management LLC now owns 118,616 shares of the medical research company’s stock valued at $27,445,000 after buying an additional 17,677 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of IQVIA by 4.0% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,418,392 shares of the medical research company’s stock worth $532,070,000 after acquiring an additional 93,194 shares in the last quarter. Cadian Capital Management LP bought a new stake in shares of IQVIA in the fourth quarter worth about $70,108,000. Nomura Holdings Inc. bought a new position in shares of IQVIA during the fourth quarter worth about $857,000. Finally, International Assets Investment Management LLC bought a new position in shares of IQVIA during the fourth quarter worth about $13,759,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Performance

Shares of IQV traded up $7.46 on Thursday, reaching $219.44. 1,099,406 shares of the company’s stock traded hands, compared to its average volume of 1,063,416. The company has a current ratio of 0.88, a quick ratio of 0.88 and a debt-to-equity ratio of 2.02. The stock has a market cap of $39.98 billion, a PE ratio of 28.96, a PEG ratio of 1.90 and a beta of 1.49. The stock’s 50 day simple moving average is $219.75 and its two-hundred day simple moving average is $229.10. IQVIA Holdings Inc. has a 52-week low of $167.42 and a 52-week high of $261.73.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, May 2nd. The medical research company reported $2.30 EPS for the quarter, beating analysts’ consensus estimates of $2.19 by $0.11. The company had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.69 billion. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. On average, analysts forecast that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on IQV. Evercore ISI cut their price objective on IQVIA from $250.00 to $230.00 and set an “outperform” rating for the company in a research report on Tuesday. Truist Financial dropped their price objective on IQVIA from $297.00 to $292.00 and set a “buy” rating for the company in a report on Friday, May 3rd. Robert W. Baird lowered their price target on IQVIA from $241.00 to $235.00 and set a “neutral” rating for the company in a report on Wednesday. Barclays lowered their price target on IQVIA from $275.00 to $255.00 and set an “overweight” rating for the company in a report on Friday, June 28th. Finally, StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a report on Sunday. Four investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average target price of $255.73.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.